Navigation Links
Britain Gets Wonder Drug That Busts Fats

A new drug that busts fats as well as tackle health problems like diabetes and smoking has been introduced in Britain//. The drug has been estimated to reduce bodyweight by up to 10 per cent.

The drug Rimonabant, also called as Acomplia, has been said to be the first drug that targets the natural body system which governs several factors controlling weight, appetite, metabolism and energy use.

In addition it has been found to have the capacity to combat a smoker’s craving for nicotine.

Drug regulators have decided to grant a license throughout the European Union for Rimonabant. And Britain is the first country to receive it. According to experts 20 per cent of Britain’s are possible candidates for treatment.

However, the drug has to also receive approval from the National Institute for Health and Clinical Excellence. The NHS also receives advice from this institute for best practice and they are not expected to receive guidance on Rimonabant for at least two years.

With the drug expected to cost £55.20 per patient per month, or £1.97 per tablet, treating even a fraction of the eligible group could cost the NHS billions.

Sanofi Aventis, the drug’s manufacturers, argues that the drug gives good value for money as against the £7 billion-per-year cost of overcoming obesity and overweight problems.

Trials were conducted on more than 6,000 patients in America and Europe. It was found that about a quarter of those patients who took Rimonabant lost more than 10 per cent of their initial body weight after a year. Half of them lost over 5 per cent of body weight. Waist circumference showed a reduction of approximately six to seven centimeters.

Significant improvements were also noted in glucose, cholesterol and triglyceride blood fats readings. In addition high-density lipoprotein fats or the good cholesterol showed an increase of 8 to 9 per cent although only half of this could be attributed to weight loss.

Trial data has also suggested that the drug can help people to give up smoking by overcoming their cravings. However, it is being marketed only to tackle obesity.

Rimonabant has been licensed for the treatment of obese patients, or overweight patients having associated risk factors such as type 2 diabetes or poor cholesterol and triglyceride readings.

It has been estimated that about one in five adults in the UK, around 10 million people, is clinically obese.

According to Anthony Barnett, a diabetes specialist from the University of Birmingham, obesity rates in Britain were climbing faster than anywhere else in the world and is expected to overtake that in the United States in 20 years.

David Haslam, a GP and clinical director of the National Obesity Forum, praised therapies such as Rimonabant calling them a “real step forward” as this was the only one, which targeted the endocannabinoid system unlike other anti obesity medications.

The endocannabinoid system regulates the appetite and Rimonabant works by blocking molecular receptors, which on activation, can trigger a cascade of biological events affecting food intake and energy use, as well as fat and glucose metabolism.

Dr Haslam, a GP from Hertfordshire said, ‘Preventative measures are not enough. Priority should be given to treatment as well as prevention.The launch of Rimonabant is important news for patients who are overweight, with type 2 diabetes, or low HDL cholesterol or high triglycerides. These patients are at high risk of developing heart disease.’

Rimonabant is scheduled to be launched later this year in the Irish Republic, Denmark, Finland, Germany and Norway. US marketing approval is expected to come by the end of the year.


'"/>




Related medicine news :

1. Couples in Britain can have “designer” babis
2. Brain drain of dentists from Kerala to Britain
3. Doctor Training Undermined In Britain Due To Shortage Of Cadavers
4. Health Care Ties To Get Stronger Between India And Britain
5. Botched Abortions Trigger Concern Over Legal Ambiguity In Britain
6. Paid-For Sex Rates In Britain Has Increased Two Fold Over The Past 10 Years
7. Rise In Waterborne And Malaria Cases Anticipated In Britain
8. Britain Toddlers To Receive Flu-Jab In Addition To The 21 Shots
9. Prince Of Wales Is Alarmed By The Obesity Wave In Britain
10. New PPUD Syndrome Prevalent Among Indian Doctors In Britain
11. Britain Announces Third Transfusion Related Mad Cow Case
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
Breaking Medicine Technology: